<DOC>
	<DOCNO>NCT01682499</DOCNO>
	<brief_summary>This pilot study evaluate feasibility intravenous calcium magnesium ( Ca/Mg ) infusion prevention taxane induce neuropathy patient early stage breast cancer receive adjuvant neo-adjuvant paclitaxel , either give every 2 week 4 cycle every week 12 week .</brief_summary>
	<brief_title>Calcium Magnesium Infusion Prevention Taxane Induced Neuropathy</brief_title>
	<detailed_description>Chemotherapy induce peripheral neuropathy ( CIPN ) major dose limit side effect many cytotoxic chemotherapy , extremely disable , cause significant loss functional ability . Calcium magnesium infusion show decreased incidence intensity neuropathy symptom relate oxaliplatin . There currently effective drug treatment modality prevention treatment taxane relate neuropathy . Given morbidity taxane induce neuropathy safety Ca/Mg infusion , reasonable ass feasibility intervention woman stage I-III breast cancer receive adjuvant neo-adjuvant paclitaxel treatment , either give every 2 week 4 cycle every week 12 week . Calcium gluconate magnesium sulfate , 1 g agent 100 ml D5W infuse 30 minute , immediately dose paclitaxel . The Ca/Mg infusion give line use give chemotherapy . The primary aim study ass paclitaxel-related neuropathy ( grade 2 great ) measure NCI Common Terminology Criteria Version 3 patient receive Ca/Mg infusion paclitaxel chemotherapy compare historical control . Secondary endpoint include measure neuropathy quality life FACT-Tax score , taxane-related neuropathy pain measure Brief Pain Inventory-Short Form ( BPI-SF ) , measure cognitive impairment use FACT-cog score .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Age &gt; 21 year History stage IIII breast cancer Patient schedule receive adjuvant neoadjuvant paclitaxel give every week 12 week give every two week 4 cycle Serum magnesium level ≤ UNL Serum calcium level ≤ UNL Serum creatinine ≤ 1.5 x UNL Signed informed consent Preexisting peripheral neuropathy grade Current treatment arrhythmia Concurrent treatment anticonvulsant , tricyclic antidepressant , neuropathic medication carbamazepine , phenytoin , gabapentin , lamotrigine , concurrent treatment neuropathic chemotherapy agent Current narcotic use</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>neuropathy</keyword>
	<keyword>taxane</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>calcium</keyword>
	<keyword>magnesium</keyword>
	<keyword>prevention</keyword>
</DOC>